Global ETD Search

Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.

Results

Showing 1 to 8 of 8 for “"gag gene"”.

  1. Investigating cross-clade immune responses in HIV-1 subtype C-infected individuals from South Africa

    … C-infected individuals. The objectives were to genetically characterise full length gag gene sequences from individuals chronically infected with HIV-1 and then assess the degree of cross-reactive immune responses in an ELlS pot assay using peptide reagents based on vaccine candidates.

    cape-town Repository record for Investigating cross-clade immune responses in HIV-1 subtype C-infected individuals from South Africa (opens in a new tab)

  2. Estimation and Comparison of HIV-Specific Substitution Matrices

    … are commonly used for sequence alignment, phylogenetic inference and sequence comparison. Empirical organism-specific substitution matrices constructed using only sequence data from a particular organism are thought to lead to more accurate analyses. In HIV research, the standard substitution …

    washington Repository record for Estimation and Comparison of HIV-Specific Substitution Matrices (opens in a new tab)

  3. Recombinant Lactobacillus as a Vaccine Vector for HIV

    … to express HIV antigens. In this study we have genetically cloned the HIV gag gene into Lactobacillus gasseri, confirmed the expression of Gag protein and evaluated the immunogenicity of the recombinant bacteria in a murine model. To evaluate the immunogenic efficacy of the novel vaccine we have …

    ncsu Repository record for Recombinant Lactobacillus as a Vaccine Vector for HIV (opens in a new tab)

  4. Development of Catalytic RNAs as Potential Anti-HIV-1 Agents

    … targeted to two different sites in the HIV-1 gag gene and a single site in the viral 5* LTR region. Efficient catalysis of each target was obtained at a physiological temperature. One of the ribozymes was expressed in CD4+ HeLa cells and was shown to be functionally active against an HIV-1 gag

    loma-linda Repository record for Development of Catalytic RNAs as Potential Anti-HIV-1 Agents (opens in a new tab)

  5. Towards Optimising Lentiviral Vectors Through Structure Informed Genome Modification

    … agents in a series of clinical applications of gene therapy, genome editing and cancer immunotherapy. 3rd generation HIV-1 derived lentiviral vectors are produced from 4 independent plasmids. Here, I focus on the transfer vector that contains the therapeutic gene and the cis-acting elements that …

    cambridge Repository record for Towards Optimising Lentiviral Vectors Through Structure Informed Genome Modification (opens in a new tab)

  6. Transcriptional and Translational Products of Avian Erythroblastosis and Avian Myeloblastosis Viruses

    … cells were found to contain a 75,000 Dalton gag-related polyprotein (p75) which contains the p19 region of the gag gene at its amino terminus. Two-dimensional tryptic peptide mapping indicated that p75 contained novel peptides in addition to those derived from p19. p75 was found to be a …

    rockefeller Repository record for Transcriptional and Translational Products of Avian Erythroblastosis and Avian Myeloblastosis Viruses (opens in a new tab)

  7. Characterizing the cellular latent reservoir of HIV-1 and the effect of immune activation on characteristics of the reservoir

    … women are underrepresented in HIV-1 research in general and more specifically in cure studies due to the paucity of research in countries outside of the global North, reservoirs and cure strategies ii need to be characterized in this context. Furthermore, while early treatment is the WHO standard …

    cape-town Repository record for Characterizing the cellular latent reservoir of HIV-1 and the effect of immune activation on characteristics of the reservoir (opens in a new tab)

  8. Human immunodeficiency virus type 1 diversity in patients initiating treatment in Northern South Africa

    … information was concealed using unique codes generated during study initiation. Participants were recruited from April 2016 to March 2017 and followed up every 3 months from June 2016 to July 2018. To determine treatment outcomes for people in UTT, demographic, socioeconomic, and clinical data …

    venda Repository record for Human immunodeficiency virus type 1 diversity in patients initiating treatment in Northern South Africa (opens in a new tab)